A
SLNO

Abingworth’s Soleno Therapeutics SLNO Stock Holding History

Abingworth’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.38M Hold
1,201,506
– – 0.78% 10
2022
Q3 		$2.01M Sell
1,201,506
-1
-0% -$2 0.69% 13
2022
Q2 		$3.17M Hold
1,201,507
– – 1.01% 11
2022
Q1 		$3.96M Buy
1,201,507
+514,667
+75% +$2.66M 1.12% 11
2021
Q4 		$4.22M Hold
686,840
– – 1.02% 14
2021
Q3 		$9.5M Hold
686,840
– – 2.16% 12
2021
Q2 		$11.6M Hold
686,840
– – 3.6% 10
2021
Q1 		$13M Hold
686,840
– – 4.48% 10
2020
Q4 		$19.9M Hold
686,840
– – 6.8% 4
2020
Q3 		$25.8M Hold
686,840
– – 5.51% 4
2020
Q2 		$22.8M Buy
686,840
+222,222
+48% +$9.63M 6.37% 5
2020
Q1 		$15.7M Hold
464,618
– – 10.41% 4
2019
Q4 		$19.9M Buy
464,618
+153,333
+49% +$3.92M 9.63% 5
2019
Q3 		$6.91M Hold
311,285
– – 4.37% 5
2019
Q2 		$12.1M Hold
311,285
– – 4.66% 5
2019
Q1 		$9.62M Hold
311,285
– – 8.61% 4
2018
Q4 		$7.98M Buy
+311,285
New +$9.09M 7.25% 4

Other funds holding SLNO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $138M AUM 38.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abingworth's SLNO Position: Q4 2022 in Review

Abingworth held its Soleno Therapeutics (SLNO) position steady in Q4 2022 at 1,201,506 shares worth $2.38M. The position accounts for 0.78% of the portfolio, ranked #10.

Abingworth first reported a position in SLNO in Q4 2018 and has held it in 17 quarters since. The position peaked at $25.8M in Q3 2020. 26 funds tracked by Wall St. Rank hold SLNO as of Q4 2022.

  • Abingworth held 1,201,506 shares of Soleno Therapeutics worth $2.38M as of Q4 2022.
  • Abingworth left its Soleno Therapeutics share count unchanged in Q4 2022.
  • Soleno Therapeutics made up 0.78% of Abingworth's portfolio in Q4 2022, its #10 holding.
  • Abingworth first reported a position in Soleno Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Abingworth's Soleno Therapeutics position peaked at $25.8M in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.